Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096213 · ClinicalTrials.gov registry record · Phase 2
S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone
A Phase 2 study of Sarcoma, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT00096213: Completed Phase 2 study of Sarcoma, sponsored by SWOG Cancer Research Network.
NCT00096213 is a Phase 2 study of Sarcoma that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 60 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096213, a Phase 2 study of Sarcoma, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Intralesional resection is a less invasive type of surgery for chondrosarcoma of the bone and may have fewer side effects and improve recovery. PURPOSE: This phase II trial is studying how well intralesional resection works in treating patients with low-grade chondrosarcoma of the bone.
Conditions Studied
Interventions
- PROCEDURE conventional surgery
Study Locations (20)
Washington
- St. Joseph Cancer Center - Bellingham
- Olympic Hematology and Oncology - Bremerton
- Skagit Valley Hospital Cancer Care Center - Mount Vernon
- Fred Hutchinson Cancer Research Center - Seattle
- Harborview Medical Center - Seattle
- Minor and James Medical, PLLC - Seattle
- Group Health Central Hospital - Seattle
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus - Seattle
- Polyclinic First Hill - Seattle
- University Cancer Center at University of Washington Medical Center - Seattle
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- William Beaumont Hospital - Royal Oak Campus - Royal Oak
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Colorado
- University of Colorado Cancer Center at University of Colorado Health Sciences Center - Aurora
Florida
- University of Florida Shands Cancer Center - Gainesville
New Mexico
- University of New Mexico Cancer Research and Treatment Center - Albuquerque
Ohio
- Akron City Hospital - Akron
Oregon
- Oregon Health & Science University Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-12 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
What the finished NCT00096213 record still lists
NCT00096213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which conventional surgery is the first listed.
NCT00096213 names 20 study sites across 10 states, led by Washington, Michigan, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00096213 about?
NCT00096213 is a clinical study titled "S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone". RATIONALE: Intralesional resection is a less invasive type of surgery for chondrosarcoma of the bone and may have fewer side effects and improve recovery. PURPOSE: This phase II trial is studying how well intralesional resection works in treating patients with low-grade chondrosarcoma of the bone.
What is the current status of trial NCT00096213?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2004-12. Estimated completion is 2009-08.
What conditions does trial NCT00096213 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT00096213?
The interventions under investigation include: conventional surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00096213?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00096213 being conducted?
This trial has 20 study locations across Arkansas, Colorado, Florida, Michigan, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00096213's enrollment target sits among peer trials
60 60th of 122 higher than 60 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia